Bone · 2026
Dyslipidemia and risk of osteonecrosis of the femoral head: A large-scale propensity score-matched cohort study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Nguyen Duy Thang, Nguyen Nguyen Thai Bao, Wu Lien-Chen, Kuo Yi-Jie, Chen Yu-Pin
Аннотация
BACKGROUND: ONFH is associated with corticosteroid use and alcohol, both disrupting lipid metabolism. Whether dyslipidemia is associated with ONFH risk remains unclear.
METHODS: We conducted a retrospective cohort study using a nationwide electronic health record database comprising 47 academic healthcare organizations. Patients aged 18-75 diagnosed with dyslipidemia from 2016 to 2019 formed the Dyslipidemia cohort (n = 1,571,192); those without formed the No Dyslipidemia cohort (n = 17,870,238). Patients with prior ONFH, corticosteroids, alcohol-related disorders, lupus erythematosus, hematologic malignancies, and other established ONFH etiologies were excluded. After 1:1 propensity score matching for age, sex, obesity, diabetes, and hypertensive diseases, each cohort comprised 1,519,388 patients. The primary outcome was incident ONFH (ICD-10-CM M87.05) at 1, 3, and 5 years.
RESULTS: ONFH risk was consistently higher in the Dyslipidemia cohort: RR 1.95 (95% CI 1.137-3.343; p = 0.013) at 1 year, 1.79 (1.464-2.189; p < 0.001) at 3 years, and 1.62 (1.440-1.815; p < 0.001) at 5 years. At 5 years, ONFH occurred in 0.049% versus 0.031% of matched controls. The E78.1 hypertriglyceridemia subgroup carried the highest risk (RR 2.33; p = 0.002), followed by hypercholesterolemia (RR 1.56) and mixed hyperlipidemia (RR 1.53). Sensitivity analysis in statin-naive cohorts yielded stronger estimates, supporting robustness.
CONCLUSION: Dyslipidemia remained associated with increased ONFH risk after excluding established competing etiologies. Hypertriglyceridemia showed the highest point estimate, requiring confirmation given limited events. Clinicians should maintain awareness of ONFH in symptomatic dyslipidemia patients; the low absolute risk does not support routine screening.
METHODS: We conducted a retrospective cohort study using a nationwide electronic health record database comprising 47 academic healthcare organizations. Patients aged 18-75 diagnosed with dyslipidemia from 2016 to 2019 formed the Dyslipidemia cohort (n = 1,571,192); those without formed the No Dyslipidemia cohort (n = 17,870,238). Patients with prior ONFH, corticosteroids, alcohol-related disorders, lupus erythematosus, hematologic malignancies, and other established ONFH etiologies were excluded. After 1:1 propensity score matching for age, sex, obesity, diabetes, and hypertensive diseases, each cohort comprised 1,519,388 patients. The primary outcome was incident ONFH (ICD-10-CM M87.05) at 1, 3, and 5 years.
RESULTS: ONFH risk was consistently higher in the Dyslipidemia cohort: RR 1.95 (95% CI 1.137-3.343; p = 0.013) at 1 year, 1.79 (1.464-2.189; p < 0.001) at 3 years, and 1.62 (1.440-1.815; p < 0.001) at 5 years. At 5 years, ONFH occurred in 0.049% versus 0.031% of matched controls. The E78.1 hypertriglyceridemia subgroup carried the highest risk (RR 2.33; p = 0.002), followed by hypercholesterolemia (RR 1.56) and mixed hyperlipidemia (RR 1.53). Sensitivity analysis in statin-naive cohorts yielded stronger estimates, supporting robustness.
CONCLUSION: Dyslipidemia remained associated with increased ONFH risk after excluding established competing etiologies. Hypertriglyceridemia showed the highest point estimate, requiring confirmation given limited events. Clinicians should maintain awareness of ONFH in symptomatic dyslipidemia patients; the low absolute risk does not support routine screening.